




RealRate

PHARMACEUTICAL 2022

NightHawk Biosciences Inc.
Rank 170 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of NightHawk Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NightHawk Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 103% points. The greatest weakness of NightHawk Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 44% points.

The company's Economic Capital Ratio, given in the ranking table, is -30%, being 246% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	99,331
Cost of Goods Sold	0
Intangible Assets	3,500
Liabilities, Current	4,721
Liabilities, Non-Current	1,149
Other Assets	15,971
Other Compr. Net Income	427
Other Expenses	1,736
Other Liabilities	3,058
Other Net Income	-128
Property and Equipment	2,158
Research and Development	18,821
Revenues	2,113
Selling, General and Administrative Expense	16,828

Output Variable	Value in 1000 USD
Assets	120,961
Liabilities	8,928
Expenses	37,386
Stockholders Equity	112,034
Net Income	-35,401
Comprehensive Net Income	-35,187
Economic Capital Ratio	-30%